Search Results - "J Litton"

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Lim, B., Ueno, N.T., Litton, J.K., Ferrarotto, R., Chang, J.T., Moulder, S.L., Lin, S.-Y.

“…High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential…”
Get full text

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial by Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.

“…In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P <…”
Get full text

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer by Fujii, T., Kogawa, T., Dong, W., Sahin, A.A., Moulder, S., Litton, J.K., Tripathy, D., Iwamoto, T., Hunt, K.K., Pusztai, L., Lim, B., Shen, Y., Ueno, N.T.

“…Although 1% has been used as cut-off for estrogen receptor (ER) positivity, several studies have reported that tumors with ER < 1% have characteristics similar…”
Get full text

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial by Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.

“…In the EMBRACA phase III trial, talazoparib (1mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician’s choice of…”
Get full text

Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population by Clifton, K., Min, Yi, Kimmel, J., Litton, J., Tripathy, D., Karuturi, M.

“…Purpose Over 40% of newly diagnosed metastatic breast cancer patients are ≥ 70 years old; however, this population is less likely to be represented in clinical…”
Get full text

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol by Meric-Bernstam, F., Brusco, L., Daniels, M., Wathoo, C., Bailey, A.M., Strong, L., Shaw, K., Lu, K., Qi, Y., Zhao, H., Lara-Guerra, H., Litton, J., Arun, B., Eterovic, A.K., Aytac, U., Routbort, M., Subbiah, V., Janku, F., Davies, M.A., Kopetz, S., Mendelsohn, J., Mills, G.B., Chen, K.

“…Next-generation sequencing in cancer research may reveal germline variants of clinical significance. We report patient preferences for return of results and…”
Get full text

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer by Gonzalez-Angulo, A.M., Akcakanat, A., Liu, S., Green, M.C., Murray, J.L., Chen, H., Palla, S.L., Koenig, K.B., Brewster, A.M., Valero, V., Ibrahim, N.K., Moulder-Thompson, S., Litton, J.K., Tarco, E., Moore, J., Flores, P., Crawford, D., Dryden, M.J., Symmans, W.F., Sahin, A., Giordano, S.H., Pusztai, L., Do, K.-A., Mills, G.B., Hortobagyi, G.N., Meric-Bernstam, F.

“…Everolimus synergistically enhances taxane-induced cytotoxicity in breast cancer cells in vitro and in vivo in addition to demonstrating a direct…”
Get full text

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer by Kim, M.M., Allen, P., Gonzalez-Angulo, A.M., Woodward, W.A., Meric-Bernstam, F., Buzdar, A.U., Hunt, K.K., Kuerer, H.M., Litton, J.K., Hortobagyi, G.N., Buchholz, T.A., Mittendorf, E.A.

“…We sought to determine the prognostic value of pathologic response to neoadjuvant chemotherapy with concurrent trastuzumab. Two hundred and twenty-nine women…”
Get full text

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence by Mittendorf, E.A., Ardavanis, A., Symanowski, J., Murray, J.L., Shumway, N.M., Litton, J.K., Hale, D.F., Perez, S.A., Anastasopoulou, E.A., Pistamaltzian, N.F., Ponniah, S., Baxevanis, C.N., von Hofe, E., Papamichail, M., Peoples, G.E.

“…AE37 is the Ii-Key hybrid of the MHC class II peptide, AE36 (HER2 aa:776–790). Phase I studies showed AE37 administered with granulocyte macrophage…”
Get full text

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial by Yu, Y., Elmeliegy, M., Litton, J.K., Tudor, I.C., Czibere, A., Zheng, J., Wang, D.D.

Get full text

Biobanking for Europe by Yuille, Martin, van Ommen, Gert-Jan, Bréchot, Christian, Cambon-Thomsen, Anne, Dagher, Georges, Landegren, Ulf, Litton, Jan-Eric, Pasterk, Markus, Peltonen, Leena, Taussig, Mike, Wichmann, H-Erich, Zatloukal, Kurt

“…Biobanks are well-organized resources comprising biological samples and associated information that are accessible to scientific investigation. Across Europe,…”
Get full text

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials by Elmeliegy, M., Yu, Y., Litton, J.K., Turner, N.C., Czibere, A., Wilson, G.G., Tudor, I.C., Zheng, J., Wang, D.D.

Get full text

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation by Rugo, H.S., Quek, R., Ettl, J., Hurvitz, S.A., Bhattacharyya, H., Hannah, A.L., Litton, J.K.

Get full text

Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy by Naing, A., Autio, K.A., Falchook, G.S., Meric-Bernstam, F., Litton, J.K., Ibrahim, N.K., Hung, A., Oft, M., Leveque, J., Patel, M.R.

Get full text

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis by Gonçalves, A., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Yerushalmi, R., Martín, M., Al-Adhami, M., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.

Get full text

We must urgently clarify data-sharing rules by Litton, Jan-Eric

“…Scientists have worked hard to ensure that Europe’s new data laws do not harm science, but one last push is needed, says Jan-Eric Litton…”
Get full text

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment by Martín, M., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Gonçalves, A., Yerushalmi, R., Markova, D., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.

Get full text

Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer by Chen, J.Q., Bao, Y., Lee, J., Murray, J.L., Litton, J.K., Xiao, L., Zhou, R., Wu, Y., Shen, X.Y., Zhang, H., Sahin, A.A., Katz, R.L., Bondy, M.L., Berinstein, N.L., Hortobagyi, G.N., Radvanyi, L.G.

“…TRPS-1 is a new GATA transcription factor that is differentially expressed in breast cancer (BC) where it been found recently to regulate…”
Get full text

Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC) by Litton, J.K., Moulder, S.L., Hess, K.R., Damodaran, S., Rauch, G.M., Candelaria, R., Adrada, B.E., Symmans, F., Murthy, R.K., Helgason, T., Clayborn, A., Prabhakaran, S., Valero, V., Thompson, A.M., Mittendorf, E.A.

Get full text

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity by Litton, J. K., Scoggins, M., Ramirez, D. L., Murthy, R. K., Whitman, G. J., Hess, K. R., Adrada, B. E., Moulder, S. L., Barcenas, C. H., Valero, V., Gomez, J. Schwartz, Mittendorf, E. A., Thompson, A., Helgason, T., Mills, G. B., Piwnica-Worms, H., Arun, B. K.

“…This study was undertaken to determine the feasibility of enrolling breast cancer patients on a single-agent-targeted therapy trial before neoadjuvant…”
Get full text